Patents by Inventor Tobias Rein
Tobias Rein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9440992Abstract: There are disclosed novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives of formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.Type: GrantFiled: December 28, 2010Date of Patent: September 13, 2016Assignee: Acturum Life Science ABInventors: Gunnar Nordvall, Colin Ray, Tobias Rein, Daniel Sohn
-
Patent number: 8158785Abstract: There are disclosed novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives of formula (I) wherein R1, R2, R3, R4 and n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.Type: GrantFiled: September 27, 2007Date of Patent: April 17, 2012Assignee: AstraZeneca ABInventors: Rolf Johansson, Sofia Karlstrom, Annika Kers, Gunnar Nordvall, Tobias Rein, Can Slivo
-
Patent number: 8088780Abstract: There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.Type: GrantFiled: April 3, 2006Date of Patent: January 3, 2012Assignee: AstraZeneca ABInventors: Gunnar Nordvall, Colin Ray, Tobias Rein, Daniel Sohn
-
Patent number: 7960395Abstract: There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) wherein R1, R2, R3, R4 and n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.Type: GrantFiled: September 27, 2007Date of Patent: June 14, 2011Assignee: AstraZeneca ABInventors: Rolf Johansson, Sofia Karlström, Annika Kers, Gunnar Nordvall, Tobias Rein, Can Slivo
-
Patent number: 7947693Abstract: There are disclosed novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives of formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.Type: GrantFiled: April 3, 2006Date of Patent: May 24, 2011Assignee: AstraZeneca ABInventors: Gunnar Nordvall, Colin Ray, Tobias Rein, Daniel Sohn
-
Publication number: 20110105537Abstract: There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) wherein R1, R2, R3, R4 and n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.Type: ApplicationFiled: January 19, 2011Publication date: May 5, 2011Applicant: AstraZeneca ABInventors: Rolf Johansson, Sofia Karlström, Annika Kers, Gunnar Nordvall, Tobias Rein, Can Slivo
-
Publication number: 20110092519Abstract: There are disclosed novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives of formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.Type: ApplicationFiled: December 28, 2010Publication date: April 21, 2011Applicant: AstraZeneca ABInventors: Gunnar Nordvall, Colin Ray, Tobias Rein, Daniel Sohn
-
Publication number: 20110028489Abstract: The present invention relates to a new use of pyrimidine derivatives of formula I, as a free base or a pharmaceutically acceptable salt thereof in the manufacture of a medicament in the treatment and/or prophylaxis of Alzheimer's Disease:Type: ApplicationFiled: August 16, 2010Publication date: February 3, 2011Inventors: Lars Andersson, Stefan Berg, Jeremy Burrows, Sven Hellberg, Fernando Huerta, Tobias Rein
-
Publication number: 20100035899Abstract: There are disclosed novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives of formula (I) wherein R1, R2, R3, R4 and n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.Type: ApplicationFiled: September 27, 2007Publication date: February 11, 2010Applicant: ASTRAZENECA ABInventors: Rolf Johansson, Sofia Karlstrom, Annika Kers, Gunnar Nordvall, Tobias Rein, Can Slivo
-
Publication number: 20090247555Abstract: There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, is pulmonary diseases such as COPD, asthma or pain.Type: ApplicationFiled: March 26, 2009Publication date: October 1, 2009Applicant: AstraZeneca ABInventors: Mikael Dahlstrom, Gunnar Nordvall, Tobias Rein, Ingemar Starke
-
Publication number: 20090124637Abstract: There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) [Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, R3, R4 and R5 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.Type: ApplicationFiled: April 3, 2006Publication date: May 14, 2009Applicant: AstraZeneca ABInventors: Gunnar Nordvall, Colin Ray, Tobias Rein, Daniel Sohn
-
Publication number: 20090105252Abstract: Compounds of formula I wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification as a base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, processes for their preparation, new intermediates used therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.Type: ApplicationFiled: October 2, 2006Publication date: April 23, 2009Applicant: AstraZeneca ABInventors: Lars Andersson, Erwan Arzel, Stefan Berg, Jeremy Burrows, Sven Hellberg, Fernando Huerta, Torben Pedersen, Tobias Rein, Didier Rotticci, Karin Staaf, Dominika Turek
-
Publication number: 20080318981Abstract: There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) wherein R1, R2, R3, R4 and n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.Type: ApplicationFiled: September 27, 2007Publication date: December 25, 2008Applicant: AstraZeneca ABInventors: Rolf Johansson, Sofia Karlstrom, Annika Kers, Gunnar Nordvall, Tobias Rein, Can Slivo
-
Publication number: 20080255106Abstract: Compounds of formula I wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification, as a base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, processes for their preparation and new intermediates used therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.Type: ApplicationFiled: October 2, 2006Publication date: October 16, 2008Applicant: AstraZeneca ABInventors: Per I. Arvidsson, Erwan Arzel, Jeremy Burrows, Helena Gyback, Tobias Rein, Didier Rotticci, Peter Soderman
-
Publication number: 20080255085Abstract: Compounds of formula I wherein X is or Y; and wherein A, Y, R1, R2, R3, R4 and R5 are as defined in the specification as a base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, processes for their preparation, new intermediates used therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.Type: ApplicationFiled: October 2, 2006Publication date: October 16, 2008Applicant: ASTRAZENECA ABInventors: Per I Arvidsson, Erwan Arzel, Jeremy Burrows, Martina Claesson, Colin Ray, Tobias Rein, Didier Rotticci, Peter Soderman
-
Publication number: 20080214560Abstract: Pyrimidine derivatives of formula I, wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification, as a base or a pharmaceutically acceptable salt thereof in the manufacture of pharmaceutical compositions and in the treatment or prophylaxis of Alzheimer's Disease.Type: ApplicationFiled: October 2, 2006Publication date: September 4, 2008Applicant: AstraZeneca ABInventors: Lars Andersson, Stefan Berg, Jeremy Burrows, Sven Hellberg, Fernando Huerta, Tobias Rein
-
Publication number: 20080214578Abstract: There are disclosed novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives of formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.Type: ApplicationFiled: April 3, 2006Publication date: September 4, 2008Inventors: Gunnar Nordvall, Colin Ray, Tobias Rein, Daniel Sohn
-
Publication number: 20080188502Abstract: The present invention relates to a compound of formula (I): as a free base or a pharmaceutically acceptable salt thereof. The present invention also relates to pharmaceutical formulations containing said compound and to the use of said compound in therapy. The present invention further relates to a process for the preparation of compound of formula (I) and to new intermediates used therein.Type: ApplicationFiled: June 27, 2007Publication date: August 7, 2008Applicant: AstraZeneca ABInventors: Jeremy Burrows, Fernando Huerta, Fredrik Lake, Torben Pedersen, Didier Rotticci, Tobias Rein, Karin Staaf, Ulrika Yngve
-
Publication number: 20080188503Abstract: The present invention relates to a compound of formula (I): as a free base or a pharmaceutically acceptable salt thereof. The present invention also relates to pharmaceutical formulations containing said compound and to the use of said compound in therapy. The present invention further relates to a process for the preparation of the compound of formula (I).Type: ApplicationFiled: June 27, 2007Publication date: August 7, 2008Applicant: AstraZenaca ABInventors: Jeremy Burrows, Fernando Huerta, Tobias Rein, Didier Rotticci, Karin Staaf, Dominika Turek
-
Publication number: 20070142386Abstract: There are disclosed novel compounds of formula (I) wherein A, R1, R2, R3 and X are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, atherosclerosis and pain.Type: ApplicationFiled: October 5, 2004Publication date: June 21, 2007Applicant: AstraZenecaInventors: Gunnar Nordvall, Tobias Rein, Daniel Sohn, Ronald Zemribo